2010•KanzoOpen access

The efficacy of virological response in treatment-naïve patients with chronic hepatitis C treated by NS3-4A protease inhibitor (telaprevir) , pegylated interferon and ribavirin for 12 weeks

Hitomi Sezaki, Fumitaka Suzuki, Norio Akuta, Miharu Hirakawa, Yusuke Kawamura, Hiromi Yatsuji, Tetsuya Hosaka, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada

Open full text 0 citations

Abstract

We investigated the efficacy of the triple treatment with telaprevir, pegylated interferon (PEG-IFN) and ribavirin for 12 weeks in treatment-naïve patients infected with hepatitis C virus (HCV) genotype 1b and high baseline viral loads. All of 10 cases became HCV-RNA negative during treatment. SVR rate attained to a high rate, 70% (7/10). Especially, SVR rate of females over 50 years old attained 100% (3/3). HCV RNA was lost from serum rapidly in patients infected with HCV-1b in high viral loads, and SVR rate of the triple treatment for 12weeks was high. Our results suggested that triple treatment with telaprevir, PEG-IFN and ribavirin could improve the efficacy in treatment-naïve patients.

Open-access reader

About this research paper

What this paper is about

We investigated the efficacy of the triple treatment with telaprevir, pegylated interferon (PEG-IFN) and ribavirin for 12 weeks in treatment-naïve patients infected with hepatitis C virus (HCV) genotype 1b and high baseline viral loads. All of 10 cases became HCV-RNA negative during treatment. SVR rate attained to a high rate, 70% (7/10). Especially, SVR rate of females over 50 years old attained 100% (3/3). HCV RNA was lost from serum rapidly in patients infected with HCV-1b in high viral loads, and SVR rate of the triple treatment for 12weeks was high. Our results suggested that triple treatment with telaprevir, PEG-IFN and ribavirin could improve the efficacy in treatment-naïve patients.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

We investigated the efficacy of the triple treatment with telaprevir, pegylated interferon (PEG-IFN) and ribavirin for 12 weeks in treatment-naïve patients infected with hepatitis C virus (HCV) genotype 1b and high baseline viral loads. All of 10 cases became HCV-RNA negative during treatment. SVR rate attained to a high rate, 70% (7/10). Especially, SVR rate of females over 50 years old attained 100% (3/3). HCV RNA was lost from serum rapidly in patients infected with HCV-1b in high viral loads, and SVR rate of the triple treatment for 12weeks was high. Our results suggested that triple treatment with telaprevir, PEG-IFN and ribavirin could improve the efficacy in treatment-naïve patients.

Key concepts: Telaprevir, Ribavirin, Pegylated interferon, Medicine, Gastroenterology, Hepatitis C virus, Internal medicine, NS3

Related papers

Back to paper searchBrowse research topicsOriginal source
The efficacy of virological response in treatment-naïve patients with chronic hepatitis C treated by NS3-4A protease inhibitor (telaprevir) , pegylated interferon and ribavirin for 12 weeks — Research Paper | ScholarLens